drugset
drugset / Trial / NCT04696393

A Study to Compare the Pharmacokinetics and Safety of Mitapivat 100 mg Tablet Formulation With Mitapivat 2 × 50 mg Tablet Formulation in Healthy Adult Participants

NCT04696393 ↗

Phase 1 Completed 26 enrolled Agios Pharmaceuticals, Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

The primary purpose of this study is to characterize and compare the pharmacokinetic profiles of mitapivat following a single dose administration of 100 mg mitapivat in two tablet formulations (50 mg and 100 mg tablet strengths) in healthy adult participants.

Timeline

Start
2021-01-06
Primary completion
2021-03-19
Completion
2021-03-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Mitapivat Small molecule 100 mg Oral

Indications

No indication recorded.